1a. Objectives (from AD-416):
The objectives of this work include 1) Determine the efficacy of bacteriophage to prevent and treat colibacillosis (Escherichia coli); 2) Determine the efficacy of bacteriophage to prevent and treat turkey coryza (Bordetella avium);and 3) Determine the efficacy of bacteriophage to prevent and treat fowl cholera (Pasteurella multocida).
1b. Approach (from AD-416):
Bacteriophage will be isolated from environmental sources targeted for the bacteria E. coli, Bordetella avium, and Pasteurella multocide. Using our established colibacilosis model we will quantitatively determine the relationship between bacteriophage titers to therapeutic efficacy by treating colibacillosis with different bacteriophage titers, and will conduct in vitro studies to determine if there are any non-specific blood factors that inhibit bacteriophage activity. The efficacy of repeated treatment of bacteriophage will be conducted by administering bacteriophage prior to challenging the birds with the disease agent, and then treating them with an additional bacteriophage administration to determine if prior exposure to high titers of bacteriophage will limit the efficacy of bacteriophage to treat colibacillosis. Bacteriophage from environmental sources will be isolated with effectiveness against Bordetella avium and Pasteurella multocida. Studies will be conducted to determine the efficacy of aerosol administration of bacteriophage to prevent disease by administrating the bacteriophage prior to challenging the birds with Bordetella avium or Pasteurella multocida.
3. Progress Report:
This project was terminated during FY12 and replaced by project 6226-32000-012-00D. Please refer to the report for that project for additional information on the continuation of this research. We have demonstrated that bacteriophage can be used to both prevent and treat the very important disease of the poultry industry known as colibacillosis, caused by avian pathogenic E. coli (APEC). We have also found that the immune system can interfere with the bacteriophage activity, but are confident that this interference can be overcome. This research clearly has demonstrated that bacteriophage can be an effective alternative to antibiotics. This research has now moved to how can we make this a practical solution to this significant poultry industry disease. To this end we have developed a new model for colibacillosis, allowing us to conduct research on practical applications of bacteriophage, which will be the next step in the pursuit of a commercially viable bacteriophage product.